MDK and esophageal squamous cell carcinoma: Treatment with iMDK, a cell-permeable imidazothiazolyl-chromenone compound that selectively inhibits endogenous MDK (Figure S8A), decreased the viability of ESCC cells in a dose-dependent manner (Figure 6A and Figure S8B).